High Risk for Invasive Meningococcal Disease Among Patients Receiving Eculizumab (Soliris) Despite Receipt of Meningococcal Vaccine. Issue 9 (September 2017) - McNamara, L. A.
Abstract : This article reviews the risk of meningococcal disease following eculizumab treatment in patients who have received the meningococcal vaccine.